Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547912 | 1.00 | MDM4 (0.53) | MDM4TP53SLC17A5CASP3HRH4 | |
| SCHEMBL800112 | 1.00 | MDM4 (0.53) | MDM4TP53SLC17A5CASP3HRH4 | |
| SCHEMBL29397967 | 1.00 | MDM4 (0.53) | MDM4TP53SLC17A5CASP3HRH4 | |
| SCHEMBL29401862 | 1.00 | MDM4 (0.53) | MDM4TP53SLC17A5CASP3HRH4 | |
| SCHEMBL3725031 | 1.00 | MDM4 (0.53) | MDM4TP53SLC17A5CASP3HRH4 | |
| SCHEMBL13978398 | 0.91 | MDM4 (0.47) | MDM4TP53SLC17A5CASP3CTSS | |
| SCHEMBL24915806 | 0.89 | MDM4 (0.50) | MDM4TP53SLC17A5CASP3MDM2 | |
| SCHEMBL30229636 | 0.89 | MDM4 (0.50) | MDM4TP53SLC17A5CASP3MDM2 | |
| SCHEMBL29221380 | 0.89 | MDM4 (0.50) | MDM4TP53SLC17A5CASP3MDM2 | |
| SCHEMBL30229510 | 0.89 | MDM4 (0.50) | MDM4TP53SLC17A5CASP3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515880-B1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF ENCODED LIBRARIES | HITGEN INC (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| EP-1692099-A1 | SOMATOSTATINE RECEPTOR SUBTYPE 1 (SSTR1) ACTIVE COMPOUNDS AND THEIR USE IN THERAPY | Oy Juvantia Pharma Ltd (FI) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005056520-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 1 (SSTR1) ACTIVE COMPOUNDS AND THEIR USE IN THERAPY | OY JUVANTIA PHARMA LTD (FI) | 2005-06-23 | — | — | WO | disclosed |
| US-20040082079-A1 | Low affinity screening method | GRAFFINITY PHARMACEUTICALS AG. (DE) | 2004-04-29 | — | — | US | disclosed |
| EP-1360489-A1 | LOW AFFINITY SCREENING METHOD | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | MDM4 1060/4885TP53 573/4885SLC17A5 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.